Skip to content

Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?

The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.

Read full article
October 7, 2014

You Own This!

  Guest blogger Laurie Halloran is the President and CEO of Halloran Consulting Group, a management consulting firm for..
Read article